For leukopenia and thrombocytopenia, Osimertinib showed the highest incidence rates among EGFR-TKIs at 8% and 9%, respectively, but these were still much lower than the chemotherapy group’s 29% and 19%. This evidence concerns the gene EGFR and Decreased total leukocyte count.